Nils Isbak - ChemoMetec Vice President Global Sales
| CHEMM Stock | DKK 473.60 6.40 1.33% |
President
Nils Isbak is Vice President Global Sales of ChemoMetec AS
| Phone | 45 48 13 10 20 |
| Web | https://chemometec.com |
ChemoMetec Management Efficiency
The company has return on total asset (ROA) of 0.3117 % which means that it generated a profit of $0.3117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4858 %, meaning that it generated $0.4858 on every $100 dollars invested by stockholders. ChemoMetec's management efficiency ratios could be used to measure how well ChemoMetec manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | PRESIDENT Age | ||
| Tahamtan Ahmadi | Genmab AS | 50 | |
| Martine Vugt | Genmab AS | 49 | |
| Anthony Mancini | Genmab AS | 52 | |
Management Performance
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 |
ChemoMetec AS Leadership Team
Elected by the shareholders, the ChemoMetec's board of directors comprises two types of representatives: ChemoMetec inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoMetec. The board's role is to monitor ChemoMetec's management team and ensure that shareholders' interests are well served. ChemoMetec's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoMetec's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christian Berg, Product Manager | ||
| Steen SoendergaardLarsen, Chief Executive Officer | ||
| Kurt Nielsen, Production and Procurement Manager | ||
| Michael Packert, Head of Production | ||
| Kristine Faerch, Director | ||
| Hans Glensbjerg, Vice Chairman of The Board, COO and Director | ||
| Martin Behrens, Chief US | ||
| Christopher MSc, VP US | ||
| Soeren Kjaerulff, Head of Research & Development | ||
| Preben Koenig, Chairman of the Board | ||
| Nils Isbak, Vice President Global Sales | ||
| Steen Sondergaard, Chief Officer | ||
| Claus Madsen, Acting Chief Executive Officer, Chief Financial Officer | ||
| Peter Reich, Independent Director | ||
| Lisbet Helles, Head of Marketing | ||
| Sren Kjrulff, Head RD | ||
| Niels Nielsen, Chief Officer | ||
| Martin Glensbjerg, Vice Chairman of the Board, Chief Operating Officer | ||
| Louise Petersen, Quality Manager | ||
| Christopher Runchel, Senior Vice President - United States |
ChemoMetec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoMetec a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 14.38 B | |||
| Shares Outstanding | 17.4 M | |||
| Shares Owned By Insiders | 10.87 % | |||
| Shares Owned By Institutions | 51.35 % | |||
| Price To Earning | 197.96 X | |||
| Price To Book | 40.83 X |
Pair Trading with ChemoMetec
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoMetec position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will appreciate offsetting losses from the drop in the long position's value.Moving against ChemoMetec Stock
| 0.54 | CARL-B | Carlsberg AS | PairCorr |
| 0.53 | CARL-A | Carlsberg AS | PairCorr |
| 0.49 | JYSK | Jyske Bank AS | PairCorr |
| 0.45 | ORSTED | Orsted AS | PairCorr |
| 0.36 | GMAB | Genmab AS | PairCorr |
The ability to find closely correlated positions to ChemoMetec could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoMetec when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoMetec - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoMetec AS to buy it.
The correlation of ChemoMetec is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoMetec moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoMetec AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoMetec can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in ChemoMetec Stock
ChemoMetec financial ratios help investors to determine whether ChemoMetec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChemoMetec with respect to the benefits of owning ChemoMetec security.